This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.93% per year. These returns cover a period from January 1, 1988 through March 2, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
earnings-outlook: Archive
MARKER THERAPEUTICS, INC. (MRKR) Reports Q4 Loss, Tops Revenue Estimates
by Zacks Equity Research
MARKER THERAPEUTICS (MRKR) delivered earnings and revenue surprises of +80.49% and +83.83%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
MRKRNegative Net Change ECORPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
TAT Technologies Ltd. (TATT) Q4 Earnings and Revenues Miss Estimates
by Zacks Equity Research
TAT Technologies (TATT) delivered earnings and revenue surprises of -6.67% and -2.07%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
TATTNegative Net Change AIRPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
DLocal (DLO) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
DLocal (DLO) delivered earnings and revenue surprises of +25.71% and +14.11%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
DLONegative Net Change FDSNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Usio Inc (USIO) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Usio (USIO) delivered earnings and revenue surprises of -1,100.00% and -3.48%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
USIONegative Net Change BTBTNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
4D Molecular Therapeutics, Inc. (FDMT) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
4D Molecular Therapeutics (FDMT) delivered earnings and revenue surprises of +180.75% and +147.86%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
FDMTNegative Net Change IGCNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Sera Prognostics, Inc. (SERA) Reports Q4 Loss, Lags Revenue Estimates
by Zacks Equity Research
Sera Prognostics (SERA) delivered earnings and revenue surprises of +5.88% and -75.00%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
SERANegative Net Change CODXPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Micron (MU) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Micron (MU) delivered earnings and revenue surprises of +38.57% and +21.67%, respectively, for the quarter ended February 2026. Do the numbers hold clues to what lies ahead for the stock?
MUPositive Net Change AEHRNegative Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
Five Below (FIVE) Tops Q4 Earnings and Revenue Estimates
by Zacks Equity Research
Five Below (FIVE) delivered earnings and revenue surprises of +8.02% and +1.14%, respectively, for the quarter ended January 2026. Do the numbers hold clues to what lies ahead for the stock?
FIVENegative Net Change SPWHPositive Net Change
earnings earnings-estimates earnings-outlook earnings-surprise industry-outlook zacks-consensus-estimate zacks-rank
South32 (SOUHY) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
South32 (SOUHY) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
SOUHYNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank
Sierra Bancorp (BSRR) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Sierra Bancorp (BSRR) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BSRRNegative Net Change
earnings-estimates earnings-estimates-revisions earnings-outlook rating-upgrade stock-price-movement zacks-consensus-estimate zacks-rank